Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk

References

• Rudd RA, Seth P, David F. Increases in drug and opioid-involved overdose deaths––United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452.
   PubMed Web of Science ®Google Scholar
• Miller H, Panahi L, Tapia D, et al. Loperamide misuse and abuse. J Am Pharm Assoc. 2017;57:S45–S50.
   Google Scholar
• Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic trends in loperamide abuse and misuse. Ann Emerg Med. 2017;69:73–78.
   PubMed Web of Science ®Google Scholar
• Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord 2007;7:S11–S18.
   PubMedGoogle Scholar
• Daniulaityte R, Carlson RG, Falck RS, et al. “I just wanted to tell you that loperamide WILL WORK”: a web-based study of extra-medical use of loperamide . Drug Alcohol Depend. 2013;130:241–244.
   PubMed Web of Science ®Google Scholar
• Mowry JB, Spyker DA, Brooks DE, et al. 2015 Annual reports of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol. 2016;54:924–1109.
   PubMed Web of Science ®Google Scholar
• Swank KA, Wu E, Kortepeter C, et al. Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse. J Am Pharm Assoc. 2017;57:S63–S67.
   Google Scholar
• Eggleston W, Clark KH, Marraffa JM. Loperamide Abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2017;69:83–86.
   PubMed Web of Science ®Google Scholar
• Kang J, Compton DR, Vaz RJ, et al. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelation from the opioid abuse epidemic. Naunyn-Schmiedeberg's Arch Pharmacol. 2016;389:1133–1137.
   Google Scholar
• Eggleston W, Nacca N, Marraffa JM. Loperamide toxicokinetics: serum concentrations in the overdose setting. Clin Toxicol. 2015;53:495–496.
   PubMed Web of Science ®Google Scholar
• Mukarram O, Hindi Y, Catalasan G, et al. Loperamide induced torsades de pointes: a case report and review of the literature. Case Rep Med. 2016; 2016:1–3.
   Google Scholar
• Wightman RS, Hoffman RS, Howland MA, et al. Not your regular high: cardiac dysrhythmias caused by loperamide. Clin Toxicol. 2016;54:454–458.
   PubMed Web of Science ®Google Scholar
• Leung G, Altshuler D, Goldenberg R, et al. Conduction disturbances and ventricular arrhythmias associated with high-dose loperamide. J Clinic Toxicol. 2016;6:1–5.
   Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463–469.
   PubMed Web of Science ®Google Scholar
• FDA. FDA warns about serious heart problems with high doses of antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. FDA Drug Safety Communications 2016.
   Google Scholar
• Jaffe JH, Kanzler M, Green J. Abuse potential of loperamide. Clin Pharmacol Ther. 1980; 28:812–819.
   PubMed Web of Science ®Google Scholar
• O'Connell CW, Schricker AA, Schneir AB, et al. High-dose loperamide abuse-associated ventricular arrhythmias. HeartRhythm Case Rep. 2016;2:232–236.
   PubMedGoogle Scholar
• Borron SW, Watts SH, Tull W, et al. Intentional misuse and abuse of loperamide: a new look at a drug with “low abuse potential.” J Emerg Med. 2017;53:73–84.
   PubMed Web of Science ®Google Scholar
• Eggleston W, Marraffa JM, Stork CM, et al. Notes from the field: cardiac dysrhythmias after loperamide abuse––New York, 2008-2016. MMWR Morb Mortal Wkly Rep. 2016;65:1276–1277.
   PubMed Web of Science ®Google Scholar
• Marraffa JM, Holland MG, Sullivan RW, et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol. 2014;52:952–957.
   PubMed Web of Science ®Google Scholar
• Spinner HL, Lonardo NW, Mulamalla R, et al. Ventricular tachycardia associated with high-dose chronic loperamide use. Pharmacotherapy. 2015;35:234–238.
   PubMed Web of Science ®Google Scholar
• Friedli G, Haenggeli CA. Loperamide overdose managed by naloxone. Lancet. 1980;1:1413
   PubMed Web of Science ®Google Scholar
• Bhatti Z, Norsworthy J, Szombathy T. Loperamide metabolite-induced cardiomyopathy and QTc prolongation. Clin Toxicol. 2017;55:659–661.
   PubMed Web of Science ®Google Scholar
• Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med. 2017;70:245–252.
   PubMed Web of Science ®Google Scholar
• Minton NA, Smith PG. Loperamide toxicity in a child after a single dose. Br Med J (Clin Res Ed). 1987;294:1383
   PubMed Web of Science ®Google Scholar
• Manubay JM, Muchow C, Sullivan MA. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim Care. 2011;38:71–vi.
   PubMed Web of Science ®Google Scholar
• Vaz RJ, Kang J, Luo Y, et al. Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K + channel. Bioorg Med Chem Lett. 2017;28:31181–31182.
   Web of Science ®Google Scholar
• Weaver LT, Richmond SW, Nelson R. Loperamide toxicity in severe protracted diarrhoea. Arch Dis Child. 1983;58:568–569.
   PubMed Web of Science ®Google Scholar
• Jodoin J, Demeule M, Fenart L, et al. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem. 2003;87:1010–1023.
   PubMed Web of Science ®Google Scholar
• Lasoff DR, Koh CH, Minns AB, et al. Loperamide trends in abuse and misuse over 13 years: 2002-2015. Pharmacotherapy. 2017;37:249–253.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006;61:538–544.
   PubMed Web of Science ®Google Scholar
• Wang E, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46:160–165.
   PubMed Web of Science ®Google Scholar
• Wang E, Casciano CN, Clement RP, et al. Evaluation of the interaction of loratadine and desloratadine with p-glycoprotein. Drug Metab Dispos. 2001;29:1080–1083.
   PubMed Web of Science ®Google Scholar
• Sadeque AJM, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics. 2000;68:231–237.
   PubMed Web of Science ®Google Scholar
• Tandy KP. Combat Methamphetamine Epidemic Act of 2005. 2017 May 7. Retrieved from https://www.deadiversion.usdoj.gov/meth/.
   Google Scholar
• Tenenbein M. Unit-dose packaging of iron supplements and reduction of iron poisoning in young children. Arch Pediatr Adolesc Med. 2005;159:557–560.
   PubMedGoogle Scholar